Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate

ADAM10 and ADAM17 have been shown to contribute to the acquired drug resistance of HER2-positive breast cancer in response to trastuzumab. The majority of ADAM10 and ADAM17 inhibitor development has been focused on the discovery of compounds that bind the active site zinc, however, in recent years,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Madoux, Franck, Dreymuller, Daniela, Pettiloud, Jean-Phillipe, Santos, Radleigh, Becker-Pauly, Christoph, Ludwig, Andreas, Fields, Gregg B., Bannister, Thomas, Spicer, Timothy P., Cudic, Mare, Scampavia, Louis D., Minond, Dmitriy
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431342/
https://ncbi.nlm.nih.gov/pubmed/28442704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-016-0013-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars